E-mail us:
service@prospectnews.com
Or call: 212 374 2800
Bank Loans - Convertibles - Distressed Debt - Emerging Markets
Green Finance - High Yield - Investment Grade - Liability Management
Preferreds - Private Placements - Structured Products
Add to balance / Manage account
Not logged in
Prospect News home
>
Main news index
>
All issuers starting with T
>
Issuers starting with T, CV only
>
All stories on Trinity Biotech plc
>
Stories on Trinity Biotech plc, CV only
Search again
Enter part or all of the issuer name:
Market:
All markets
No structured products
Bank loans
Canadian bonds
CLOs
Convertibles
Distressed debt
Emerging markets
High yield
Investment grade
Liability management
Municipals
PIPEs
Preferreds
Private placements
All leveraged markets
Structured products
Market: BK = Bank loans, CV = Convertibles, DD = Distressed Debt, EM = Emerging Markets, HY = High Yield, IG = Investment Grade, LM = Liability Management, MU = Municipals, PP = PIPEs, PF = Preferreds, PV = Private Placements, SP = Structured Products
Recent items, highlighted in orange, are $4.00 each.
All others are $1.00 each. Headlines in
gray
are not currently covered by your subscription.
Trinity Biotech plc
12/15/2021
CVLM
Trinity Biotech enters into exchange agreements for $99.7 million of notes
4/24/2015
CV
Market Commentary:
Spectranetics gains on swap after quarterly loss; new Cinedigm trades at 101 to 103
4/24/2015
CV
Market Commentary:
Morning Commentary: New Cinedigm convertibles trade at 101 to 103; Pernix around par
4/9/2015
CV
Trinity Biotech greenshoe lifts 30-year exchangeables to $115 million
4/2/2015
CV
Market Commentary:
New Trinity Biotech quiet, shares lower; overall market muted ahead of holiday weekend
4/2/2015
CV
Market Commentary:
Morning Commentary: New Trinity Biotech quiet, shares lower; market muted ahead of holiday
4/2/2015
CV
New Issue: Trinity Biotech sells $100 million 30-year exchangeables at 4%, up 15%
4/1/2015
CV
Market Commentary:
Egalet seen at par; Trinity Biotech on tap; UTi Worldwide up after disappointing results
4/1/2015
CV
Trinity Biotech to price $100 million of 30-year exchangeables
©2025 Prospect News. This page is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies, faxing, photocopying or any other form of reproduction.
